Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Vinburnine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.55 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.90 |
| ▸ | TSHR | P16473 | 2/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | PDE1A | P54750 | 11/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinburnine SCHEMBL1897014 | 1.00 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL10509950 | 1.00 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL14029339 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29388881 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL456385 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29771389 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29391038 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL689181 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL689180 | 0.95 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL636902 | 0.86 | CYP3A4 (0.78) | CYP3A4CYP2D6LMNANR1I2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120231010-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8198292-B2 | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof | OSTEOGENEX, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-2320896-A2 | VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteogenex Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100003324-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002835-A2 | VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231010-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | BMP6, ATP6V1B1, WNT1 | KCNH2 2482/4885HRH1 3994/4885CYP3A4 3615/4885 |
| US-20100003324-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | BMP6, ATP6V1B1, WNT1 | KCNH2 2482/4885HRH1 3994/4885CYP3A4 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.